- Hawaii's Kilauea volcano erupts, spewing columns of lava
- El Salvador Congress votes to end ban on metal mining
- Five things to know about Panama Canal, in Trump's sights
- NBA fines Minnesota guard Edwards $75,000 for outburst
- Haitians massacred for practicing voodoo were abducted, hacked to death: UN
- Inter beat Como to keep in touch with leaders Atalanta
- Mixed day for global stocks as market hopes for 'Santa Claus rally'
- Man Utd boss Amorim questions 'choices' of Rashford's entourage
- Trump's TikTok love raises stakes in battle over app's fate
- Is he serious? Trump stirs unease with Panama, Greenland ploys
- England captain Stokes to miss three months with torn hamstring
- Support grows for Blake Lively over smear campaign claim
- Canada records 50,000 opioid overdose deaths since 2016
- Jordanian, Qatari envoys hold talks with Syria's new leader
- France's second woman premier makes surprise frontline return
- France's Macron announces fourth government of the year
- Netanyahu tells Israel parliament 'some progress' on Gaza hostage deal
- Guatemalan authorities recover minors taken by sect members
- Germany's far-right AfD holds march after Christmas market attack
- European, US markets wobble awaiting Santa rally
- Serie A basement club Monza fire coach Nesta
- Mozambique top court confirms ruling party disputed win
- Biden commutes almost all federal death sentences
- Syrian medics say were coerced into false chemical attack testimony
- NASA solar probe to make its closest ever pass of Sun
- France's new government to be announced Monday evening: Elysee
- London toy 'shop' window where nothing is for sale
- Volkswagen boss hails cost-cutting deal but shares fall
- Accused killer of US insurance CEO pleads not guilty to 'terrorist' murder
- Global stock markets mostly higher
- Not for sale. Greenland shrugs off Trump's new push
- Sweden says China blocked prosecutors' probe of ship linked to cut cables
- Acid complicates search after deadly Brazil bridge collapse
- Norwegian Haugan dazzles in men's World Cup slalom win
- Arsenal's Saka out for 'many weeks' with hamstring injury
- Mali singer Traore child custody case postponed
- France mourns Mayotte victims amid uncertainy over government
- UK economy stagnant in third quarter in fresh setback
- Sweden says China denied request for prosecutors to probe ship linked to cut undersea cables
- African players in Europe: Salah leads Golden Boot race after brace
- Global stock markets edge higher as US inflation eases rate fears
- German far-right AfD to march in city hit by Christmas market attack
- Ireland centre Henshaw signs IRFU contract extension
- Bangladesh launches $5bn graft probe into Hasina's family
- US probes China chip industry on 'anticompetitive' concerns
- Biden commutes sentences for 37 of 40 federal death row inmates
- Clock ticks down on France government nomination
- 'Devastated' Australian tennis star Purcell provisionally suspended for doping
- Mozambique on edge as judges rule on disputed election
- Mobile cinema brings Tunisians big screen experience
Radius Pharmaceuticals Expands Abaloparatide Licensing Agreement with Theramex Granting Additional Commercialization Rights Including Mexico, Canada, South Africa, Israel, and Russia
Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today it has granted Theramex the exclusive commercialization rights to ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures, for Mexico, Canada, Israel, South Africa, and Russia. Theramex will also have the opportunity to commercialize ELADYNOS® in other agreed upon unpartnered regions. Abaloparatide is marketed in the U.S. by Radius under the tradename TYMLOS®.
Under the License Agreement, Radius will receive an upfront and milestone payment plus tiered royalties.
"Theramex has been an excellent collaborative partner, and we are very pleased to expand our abaloparatide partnership to include additional important global markets," said Scott Briggs, Chief Executive Officer of Radius. "Radius is committed to making abaloparatide accessible to patients, and the expansion of our existing partnership helps provide access to additional patients in need of osteoporosis treatment options."
"Following the launch of abaloparatide in Europe, we are excited to bring this innovative product to more patients globally and drive further growth through our direct markets and our commercial partnerships. This agreement expands our successful relationship with Radius, and we look forward to continuing our close collaboration," said Rob Stewart, Chief Executive Officer of Theramex.
In addition to these new territories, Theramex will continue to commercialize and distribute ELADYNOS® on an exclusive basis in the European Economic Area, the United Kingdom, Australia, and Brazil. ELADYNOS® received approval in the European Economic Area in December 2022 and Australia in November 2024 and has been launched in select countries.
About Radius:
Radius is a global biopharmaceutical company dedicated to transforming the future for underserved, global patient populations in bone health and related areas. Radius' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 to increase bone density in men with osteoporosis at high risk for fracture. Radius also has an exclusive licensing and distribution agreement for the U.S. rights to BINOSTO® (alendronate sodium) effervescent tablet for oral solution, expanding the Company's presence in bone health.
About Theramex:
Theramex is a leading global specialty pharmaceutical company dedicated to women and their health. Theramex supports women at different stages of their lives by providing a broad portfolio of innovative and established brands covering osteoporosis, contraception, fertility, menopause and uterine health. Theramex's commitment is to listen to and understand its patients, serve their needs and offer healthcare solutions to help improve their lives. Theramex's vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through different stages of their life.
Contacts:
Al Medwar: Senior Vice President, Business and Corporate Development, Radius
Email: [email protected]
Edward Rees: Chief Corporate Development Officer, Theramex
Email: to [email protected]
SOURCE: Radius Health
X.Karnes--AMWN